GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » NetraMark Holdings Inc (XCNQ:AIAI) » Definitions » EPS (Diluted)

NetraMark Holdings (XCNQ:AIAI) EPS (Diluted) : C$-0.04 (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is NetraMark Holdings EPS (Diluted)?

NetraMark Holdings's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was C$-0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.04.

NetraMark Holdings's EPS (Basic) for the three months ended in Dec. 2023 was C$-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.04.

NetraMark Holdings's EPS without NRI for the three months ended in Dec. 2023 was C$-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.04.

During the past 3 years, the average EPS without NRIGrowth Rate was -154.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 4 years, NetraMark Holdings's highest 3-Year average EPS without NRI Growth Rate was -154.20% per year. The lowest was -154.20% per year. And the median was -154.20% per year.


NetraMark Holdings EPS (Diluted) Historical Data

The historical data trend for NetraMark Holdings's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NetraMark Holdings EPS (Diluted) Chart

NetraMark Holdings Annual Data
Trend Sep20 Sep21 Sep22 Sep23
EPS (Diluted)
-0.01 -0.20 -0.34 -0.28

NetraMark Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.18 -0.05 -0.03 - -0.01

Competitive Comparison of NetraMark Holdings's EPS (Diluted)

For the Health Information Services subindustry, NetraMark Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NetraMark Holdings's PE Ratio Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, NetraMark Holdings's PE Ratio distribution charts can be found below:

* The bar in red indicates where NetraMark Holdings's PE Ratio falls into.



NetraMark Holdings EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

NetraMark Holdings's Diluted EPS for the fiscal year that ended in Sep. 2023 is calculated as

Diluted EPS (A: Sep. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-14.169-0)/49.673
=-0.29

NetraMark Holdings's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-0.853-0)/65.873
=-0.01

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NetraMark Holdings  (XCNQ:AIAI) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


NetraMark Holdings EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of NetraMark Holdings's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


NetraMark Holdings (XCNQ:AIAI) Business Description

Traded in Other Exchanges
Address
1655 Dupont Street, Suite 101, Toronto, ON, CAN, M6P 3T1
NetraMark Holdings Inc is focused on the application of a totally unique Artificial Intelligence (AI) / Machine Learning (ML) solution targeted at the pharmaceutical industry in order to de-risk clinical trials. NetraMark has a proprietary technology that is capable of cutting through the combinatorial complexity that comes with dealing with heterogeneous patient populations to extract precisely defined personas of patients with respect to placebo and drug response, in addition to tolerability and adverse events. By using the client's own contemporaneous data, and having the capacity to learn from small data, the NetraAI tech extracts these personas to equip pharmaceutical companies with strategies to optimize their next trials for success.
Executives
Andrew Parks Director

NetraMark Holdings (XCNQ:AIAI) Headlines

No Headlines